About Bitterroot Bio
Bitterroot Bio is a privately held biotechnology company pioneering the field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health. Its lead program, BRB-002, is a novel anti-CD47 protein therapy designed to reduce inflammatory plaque burden in atherosclerotic cardiovascular disease. The company develops and delivers immunotherapy-based medicines for patients with cardiovascular disease, targeting a patient population underserved by existing treatments.
Company details
Funding
Total raised
$145M
Last stage
Series A
Investors
Founders
Irving L. Weissman
Professor of Biology and Founding Director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University; Member, National Academy of Sciences. Previously co-founded Forty Seven, Inc. (acquired by Gilead for ~$5B in 2020).
Nicholas Leeper
MD; Chief of Vascular Medicine, Professor, and Director of Vascular Research at Stanford University. Co-founded Bitterroot Bio based on his CD47 cardiovascular disease research.
Lou Lange
MD, PhD; General Partner at Asset Management Ventures; former Chairman and CEO of CV Therapeutics.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.